about
Transfer of the antidepressant mirtazapine into breast milkMirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: evidence from the bench and the bedsideNeuraxial opioid-induced pruritus: An updatePharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoringPharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug responseSummary of information on human CYP enzymes: human P450 metabolism data.What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs.Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. A World Health Organization project.Review of the use of mirtazapine in the treatment of depression.Enantiomeric antidepressant drugs should be considered on individual merit.Antidepressant drugs in the elderly--role of the cytochrome P450 2D6.Repeated mirtazapine nullifies the maintenance of previously established methamphetamine-induced conditioned place preference in rats.The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.Stereo-specific LC and LC-MS bioassays of antidepressants and psychotics.Mirtazapine: a review of its clinical efficacy and tolerability.Aging and clinical pharmacology: implications for antidepressants.Application of microarray technology in psychotropic drug trials.The pharmacologic management of insomnia in patients with HIV.Antidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neuronsA review of therapeutic uses of mirtazapine in psychiatric and medical conditions.Gender and interindividual variability in pharmacokinetics.Sex differences in the psychopharmacological treatment of depression.Chiral determination of antidepressant drugs and their metabolites in biological samples.Clinically significant drug interactions with newer antidepressants.Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic.Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation.Pharmacokinetics of antidepressants in patients with hepatic impairment.Update in feline therapeutics: clinical use of 10 emerging therapies.Psychotherapeutic Agents in End-Stage Renal Disease.A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child-Pugh Classification.Inhibition of mirtazapine metabolism by Ecstasy (MDMA) in isolated perfused rat liver model.Hypotension following cardiac surgery associated with paroxetine and mirtazapine withdrawal.A Rapid and Sensitive HPLC-Fluorescence Method for Determination of Mirtazapine and Its two Major Metabolites in Human PlasmaAcute hepatitis after starting pinaverium bromide in a patient taking mirtazapine.Psychiatric issues in renal failure and dialysis.Genetic polymorphisms of CYP1A2, CYP3A4, CYP3A5, pregnane/steroid X receptor and constitutive androstane receptor in 207 healthy Spanish volunteers.Mirtazapine in the treatment of mood and anxiety disorders.Phase II trial of mirtazapine for cancer-related cachexia and anorexia.Fluvoxamine augmentation increases serum mirtazapine concentrations three- to fourfold.Mirtazapine may have the propensity for developing a restless legs syndrome? A case report.
P2860
Q24564759-8BDDA6C4-8414-46C7-9071-6285FAC64BDBQ24622161-700543B2-7574-4C4A-826F-7193E2BE1E21Q27004192-AF7B766F-D896-41C8-9BD1-EDAB8AB844CAQ27027293-83B15C15-B62E-4F3E-8F01-BF9F16B00429Q28252209-3B47447B-0455-4419-862F-214BC3DD11A3Q32103802-8B919764-9239-47DE-82BF-EE9F2B5510E0Q33278984-49690C2D-C78C-4F84-95B1-32FCE0EF6877Q34185001-F4AC8522-617E-4CDC-B438-F20EED1A73C5Q34190102-E8C0EB32-FA5A-42E8-8AC8-788675C17A9FQ34982628-654D1915-AAAF-4396-B9E3-3EC300A08D43Q35106246-F1C04D22-C20C-441C-8227-795265EC25E3Q35206777-A6781116-5604-40F5-82FE-E7C236685CEAQ35236618-B995E535-80C2-4831-8CD9-4C72BDF86CA3Q35376254-11D7DBB5-6A75-4F7A-A7AD-BA1A71AA6312Q36150725-F7A723A1-9DD7-4CDC-B37B-C80636FDDAC2Q36261418-C1C488B4-B153-4C9B-A698-935BDD573240Q36511697-C048698C-500D-4D71-993D-0D0A0D8F1218Q37234441-D7F601F4-C8DA-4B0F-BFDE-42E2F0B983C0Q37236791-0A1982D4-E708-4788-83F2-B3644FB9A9EAQ37533880-7593A3D1-176D-4B6A-A3F9-4ACE34643EACQ37550556-D47C321D-D03D-4318-9B91-FE9B8AF85365Q37618539-C36ED0CA-6D06-4840-A2D5-7D3F816A6065Q37810213-0D331859-6223-4EAB-B02C-5C0A3399C4CFQ37968621-65F5412D-1A6D-4A6B-86AE-710B240641FAQ38154915-94D1D24D-4EE9-4040-935B-1ECF52E3700AQ38245124-6B90C20C-7A2A-4959-9016-45F96EF97245Q38253564-C9F82685-8CBB-4A1F-BA9E-EDE827C9D0B2Q38363411-11E99A9F-A091-445D-A133-DEB3D6A1B103Q38413315-845FA91F-5551-4253-B1FE-DF59C0FC335FQ40839485-563B03DA-75F4-44F9-AA3C-374EE3265693Q41007402-41F5E5C7-324F-44CF-B81D-46AB3F8E6F7CQ41882784-305A492C-C009-4386-8864-2B9BA5D0CBF8Q41973647-6F38F6A4-ED4E-40E4-8F9A-45DC303A6BACQ42206749-1D88BC5C-48D4-4A6B-9AAA-AA78F0E12D85Q42928181-2429B76D-0171-45A0-8C47-BEFD30780FEAQ43135352-B27C30C9-23FB-4BFB-8543-5CB84690C702Q43265616-80E84E9A-C09F-4BF3-A3BE-30C3F8D78B35Q43272312-E6E605D4-AAA6-49AA-8F7B-56BCC8F7EA29Q43776191-D6EC86E5-8FC6-43BC-BBD0-D3C48DDED06DQ43959236-6A5B7F5E-D66C-444D-AE02-036CE43EFD5E
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Clinical pharmacokinetics of mirtazapine.
@ast
Clinical pharmacokinetics of mirtazapine.
@en
type
label
Clinical pharmacokinetics of mirtazapine.
@ast
Clinical pharmacokinetics of mirtazapine.
@en
prefLabel
Clinical pharmacokinetics of mirtazapine.
@ast
Clinical pharmacokinetics of mirtazapine.
@en
P2093
P1476
Clinical pharmacokinetics of mirtazapine.
@en
P2093
Delbressine LP
P304
P356
10.2165/00003088-200038060-00001
P577
2000-06-01T00:00:00Z
P6179
1042282354